Earnings History Data for Reata Pharmaceuticals, Inc. (RETA) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress and inflammation to address the unmet medical needs of serious or life-threatening diseases. Reata Pharmaceuticals, Inc. is based in Irving, United States.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
10-05-2023	PM	6:40 AM ET (May 10)	RETA	Reata Pharmaceuticals, Inc.	3,850	-3.14	-2.34	-2.03	Reata Pharmaceuticals Non-GAAP EPS of -$1.81 in-line, revenue of $0.2M beats by $0.04M [5/10/2023 6:41 AM]	89.99	-15.38 (-14.60%)	90.00	-15.37 (-14.59%)	18.47 - 106.69	4,729,955	460,000	118,610
Reata Pharmaceuticals Q1 2023 Earnings Preview [5/9/2023 11:40 AM] Reata Pharmaceuticals Non-GAAP EPS of -$1.81 in-line, revenue of $0.2M beats by $0.04M [5/10/2023 6:41 AM] Reata sheds 18% after halting kidney disease programs [5/10/2023 10:06 AM]
08-11-2022	PM	6:45 AM ET (Nov 8)	RETA	Reata Pharmaceuticals, Inc.	1,190	-2.16	-2.35	-1.97	Reata Pharmaceuticals Non-GAAP EPS of -$1.47 beats by $0.58, revenue of $0.54M misses by $0.19M [11/8/2022 6:47 AM]	40.07	5.17 (14.81%)	36.00	1.10 (3.15%)	18.47 - 114.80	1,915,202	660,000	2,481
Reata Pharmaceuticals Q3 2022 Earnings Preview [11/7/2022 1:07 PM] Reata Pharmaceuticals Non-GAAP EPS of -$1.47 beats by $0.58, revenue of $0.54M misses by $0.19M [11/8/2022 6:47 AM] Reata rises 15% as omaveloxolone moves ahead in FDA review process; plans EU filing [11/8/2022 12:31 PM] Reata Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs [Nov-08-22 06:40AM]
08-08-2022	PM	6:40 AM ET (Aug 8)	RETA	Reata Pharmaceuticals, Inc.	1,160	-2.02	-1.90	2.00	Reata Pharmaceuticals Non-GAAP EPS of -$1.36 beats by $0.61, revenue of $0.76M misses by $0.7M [8/8/2022 6:50 AM]	24.05	-11.65 (-32.63%)	27.66	-8.04 (-22.52%)	20.23 - 125.27	3,464,642	300,000	53,374
Reata Pharmaceuticals Non-GAAP EPS of -$1.36 beats by $0.61, revenue of $0.76M misses by $0.7M [8/8/2022 6:50 AM] Reata Pharma falls 22% on Q2 revenue miss [8/8/2022 9:17 AM] Reata drops 33%, most since December; Goldman sees favorable risk reward profile [8/8/2022 3:18 PM] Reata Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs [Aug-08-22 06:45AM]
10-05-2022	PM	6:45 AM ET (May 10)	RETA	Reata Pharmaceuticals, Inc.	842.48	-2.03	-2.26	-1.86	Reata Pharmaceuticals Non-GAAP EPS of -$1.33 beats by $0.63, revenue of $0.91M misses by $0.64M [5/10/2022 6:44 AM]	24.83	4.12 (19.89%)	20.71	0.0 (0.00%)	20.24 - 153.41	614,037	673,655	78,575
Reata Pharmaceuticals Q1 2022 Earnings Preview [5/9/2022 12:20 PM] Reata Pharmaceuticals Non-GAAP EPS of -$1.33 beats by $0.63, revenue of $0.91M misses by $0.64M [5/10/2022 6:44 AM] Reata Pharma surges as Goldman sets a Street high target [5/10/2022 11:57 AM] Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates [May-09-22 08:25AM] Reata Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs [May-10-22 06:40AM] Reata Pharmaceuticals, Inc. (RETA) Reports Q1 Loss, Misses Revenue Estimates [May-10-22 07:55AM] Reata (RETA) Q1 Earnings Top, Omaveloxolone MAA Likely in Q4 [May-10-22 10:45AM]
28-02-2022	PM	6:40 AM ET (Feb 28)	RETA	Reata Pharmaceuticals, Inc.	930.90	-2.35	-2.31	-1.90	Reata Pharmaceuticals Non-GAAP EPS of -$1.59 beats by $0.34, revenue of $0.93M misses by $0.83M [2/28/2022 6:53 AM]	31.38	5.25 (20.09%)	24.00	-2.13 (-8.15%)	22.71 - 153.41	2,349,907	480,000	2,418
Reata Pharmaceuticals Non-GAAP EPS of -$1.59 beats by $0.34, revenue of $0.93M misses by $0.83M [2/28/2022 6:53 AM] Reata Pharmaceuticals down 5% on FDA rejection, revenue miss [2/28/2022 8:31 AM] Reata Pharmaceuticals Receives Complete Response Letter From The FDA for Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport Syndrome [Feb-25-22 05:30PM] Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results and Provides an Update on Clinical Development Programs [Feb-28-22 06:45AM] FDA Strikes Off Reata Pharma's Bardoxolone Application For Rare Kidney Disease [Feb-28-22 06:09AM] Reata Pharmaceuticals, Inc. (RETA) Reports Q4 Loss, Lags Revenue Estimates [Feb-28-22 08:05AM] Reata's (RETA) Q4 Earnings Miss Mark, Revenues Decline Y/Y [Feb-28-22 12:35PM] Reata Pharmaceuticals Shares Rise 22% After Fourth Quarter Earnings [Feb-28-22 08:19AM]
08-11-2021	PM	6:45 AM ET (Nov 8)	RETA	Reata Pharmaceuticals, Inc.	3,710	-1.97	-2.32	-1.94	Reata Pharmaceuticals EPS beats by $0.62, beats on revenue [11/8/2021 6:48 AM]	106.83	1.51 (1.43%)	105.32	0.0 (0.00%)	76.34 - 186.82	248,628	190,000	40,405
Reata Pharmaceuticals EPS beats by $0.62, beats on revenue [11/8/2021 6:48 AM] Reata up 6% premarket following Q3 2021 earnings beat [11/8/2021 9:05 AM] Reata Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs [Nov-08-21 06:40AM] Reata Pharmaceuticals, Inc. (RETA) Reports Q3 Loss, Tops Revenue Estimates [Nov-08-21 07:55AM] Reata Pharmaceuticals, inc (RETA) Q3 2021 Earnings Call Transcript [Nov-08-21 05:00PM]
09-08-2021	AH	4:00 PM ET (Aug 9)	RETA	Reata Pharmaceuticals, Inc.	4,550	-2.00	-2.13	-2.03	Reata Pharmaceuticals EPS beats by $0.57, beats on revenue [8/9/2021 4:31 PM]	99.90	-22.23 (-18.20%)	102.99	-19.14 (-15.67%)	76.34 - 186.82	2,491,200	210,000	27,518
Reata Pharmaceuticals EPS beats by $0.57, beats on revenue [8/9/2021 4:31 PM] Reata drops over 10% after announcing issues in marketing application for kidney disease drug [8/9/2021 10:33 PM] Reata Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs [Aug-09-21 04:01PM] Reata Pharmaceuticals, Inc. (RETA) Reports Q2 Loss, Tops Revenue Estimates [Aug-09-21 05:25PM] Reata Pharmaceuticals, inc (RETA) Q2 2021 Earnings Call Transcript [Aug-10-21 12:00AM] Reata (RETA) Stock Down Despite Q2 Earnings & Sales Beat [Aug-10-21 09:54AM] Why Reata Pharmaceuticals Stock Is Diving Today Despite Q2 Beats [Aug-10-21 04:15PM]
06-05-2021	PM	6:35 AM ET (May 6)	RETA	Reata Pharmaceuticals, Inc.	3,630	-1.86	-2.18	-1.47	Reata Pharmaceuticals EPS beats by $0.30, misses on revenue [5/6/2021 6:45 AM]	93.28	2.28 (2.51%)	93.28	0.0 (0.00%)	84.17 - 186.82	340,696	390,000	4,012
Reata Pharmaceuticals EPS beats by $0.30, misses on revenue [5/6/2021 6:45 AM] Reata Pharmaceuticals, Inc. to Host Earnings Call [May-06-21 06:30AM] Reata Pharmaceuticals, Inc. Announces First Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs [May-06-21 06:45AM] Reata Pharmaceuticals, Inc. (RETA) Reports Q1 Loss, Lags Revenue Estimates [May-06-21 08:05AM] We Think Reata Pharmaceuticals (NASDAQ:RETA) Can Afford To Drive Business Growth [May-06-21 07:20AM] Reata Pharmaceuticals, Inc. (RETA) Q1 2021 Earnings Call Transcript [May-06-21 08:30PM]
01-03-2021	PM	6:45 AM ET (Mar 1)	RETA	Reata Pharmaceuticals, Inc.	4,520	-1.90	-2.14	-5.91	Reata Pharmaceuticals EPS beats by $0.45, beats on revenue [3/1/2021 6:39 AM]	126.99	4.73 (3.87%)	122.75	0.49 (0.40%)	88.17 - 209.91	344,195	254,120	686
Reata Pharmaceuticals EPS beats by $0.45, beats on revenue [3/1/2021 6:39 AM] Reata Pharma submits bardoxolone application in U.S. for kidney disease [3/1/2021 6:42 AM] Reata Pharmaceuticals posts Q4 results, cash guidance [3/1/2021 12:15 PM] Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results and Provides an Update on Clinical Development Programs [Mar-01-21 06:35AM] Reata Pharmaceuticals, Inc. to Host Earnings Call [Mar-01-21 06:30AM]
09-11-2020	PM	6:45 AM ET (Nov 9)	RETA	Reata Pharmaceuticals, Inc.	4,310	-1.94	-2.10	-1.32	Reata Pharmaceuticals EPS beats by $0.54, beats on revenue [11/9/2020 6:49 AM]	175.14	43.26 (32.80%)	159.37	27.48 (20.84%)	88.17 - 257.96	1,203,073	191,558	44,585

10-08-2020	PM	6:45 AM ET (Aug 10)	RETA	Reata Pharmaceuticals, Inc.	5,100	-2.03	-2.22	-1.14	Reata Pharmaceuticals EPS beats by $0.89, beats on revenue [8/10/2020 6:47 AM]	104.24	-51.96 (-33.26%)	107.00	-49.20 (-31.50%)	70.00 - 257.96	2,880,125	177,269	55,852